Seres Therapeutics, Inc.
MCRB
$9.28
-$0.80-7.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.64M | 88.78M | -32.87M | -40.13M | -41.25M |
| Total Depreciation and Amortization | 10.29M | 1.40M | 1.42M | 1.56M | 10.53M |
| Total Amortization of Deferred Charges | 0.00 | 463.00K | 485.00K | 465.00K | 409.00K |
| Total Other Non-Cash Items | -3.40M | -115.73M | 7.79M | 12.03M | -1.80M |
| Change in Net Operating Assets | -30.13M | -9.59M | -16.64M | -9.15M | -15.39M |
| Cash from Operations | -38.88M | -34.68M | -39.81M | -35.24M | -47.50M |
| Capital Expenditure | -90.00K | -129.00K | -99.00K | -62.00K | -877.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | 141.27M | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | 1.40M | -- | 0.00 |
| Cash from Investing | -90.00K | 141.14M | 1.30M | -62.00K | -877.00K |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | 0.00 | -127.91M | -- | -- | 0.00 |
| Issuance of Common Stock | 1.74M | 17.03M | 0.00 | 18.76M | 6.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.74M | -110.87M | 0.00 | 18.76M | 6.43M |
| Foreign Exchange rate Adjustments | -1.00K | -- | -- | -- | 0.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.24M | -4.41M | -38.51M | -16.54M | -41.95M |